Enable social media cookies to share Would Mark Minervini consider XERIS BIOPHARMA HOLDINGS INC (NASDAQ:XERS) a top stock pick? By Mill Chart Last update: Apr 7, 2025 Growth investors are looking for stocks showing high revenue and EPS growth. We will have a look here to see if XERIS BIOPHARMA HOLDINGS INC (NASDAQ:XERS) is suited for growth investing. Investors should of course do their own research, but we spotted XERIS BIOPHARMA HOLDINGS INC showing up in our Minervini growth screen, so it may be worth spending some more time on it. XERS passes the Minervini Trend Template check! XERS checks all the boxes when evaluating the Minervini Trend Template. This is a set of basic technical criteria to identify stocks in strong uptrends: ✔ Relative Strength is above 70.✔ Current price is within 25% of it's 52-week high.✔ Current price is at least 30% above it's 52-week low.✔ The current price is above the 50-, 150- and 200-day SMA price line.✔ The SMA(200) is trending upwards.✔ The SMA(150) is above the SMA(200)✔ The SMA(50) is above the SMA(150) and the SMA(200) Why XERS may be interesting for high growth investors. Every stock receives a High Growth Momentum Rating (HGM) from ChartMill, ranging from 0 to 10. This rating assesses various growth and profitability aspects, including historical and projected EPS and revenue growth. XERS boasts a 4 out of 10: Explosive Earnings Growth XERS has shown positive momentum in its earnings per share (EPS) on a quarter-to-quarter (Q2Q) basis, with a 70.0% increase. This reflects the company's successful execution of its business strategies and its commitment to delivering improved financial results.The earnings per share (EPS) growth of XERS is accelerating: the current Q2Q growth of 70.0% is above the previous quarter Q2Q growth of -22.22%. Earnings momentum and acceleration are key for high growth systems.The recent q2q revenue growth of 35.39% of XERS showcases the company's ability to generate increasing revenue in a short period, reflecting its positive growth trajectory.Accelerating Sales growth for XERS: the current Q2Q growth of 35.39% exceeds the previous quarter Q2Q growth of 12.31%.XERS has demonstrated strong 1-year revenue growth of 23.88%, reflecting revenue momentum and its ability to generate consistent top-line expansion. This growth underscores the company's strong market position and its potential for future success.Analysts' average next Quarter EPS Estimate for XERS has witnessed a 28.89% change in the last 3 months, underscoring the evolving market expectations towards the company's EPS prospects. Profitability & Financial Strength With positive growth in its operating margin over the past year, XERS showcases its ability to improve profitability through effective cost control and operational efficiency. This growth underscores the company's commitment to enhancing its financial performance.The free cash flow (FCF) of XERS has seen steady growth over the past year, indicating enhanced cash flow generation and financial health. This trend underscores the company's effective capital management and its ability to generate sustainable cash flows. Strong Market Performance The Relative Strength (RS) of XERS has been consistently solid, with a current 98.32 rating. This highlights the stock's ability to exhibit sustained price strength and signifies its competitive advantage. Why is XERS a setup? ChartMill provides a Setup Rating for each stock. This rating, ranging from 0 to 10, assesses the level of consolidation in the stock based on multiple short-term technical indicators. Currently, XERS has a 1 as its setup rating, indicating its current consolidation status. Although XERS has an excellent technical rating, it does not present a decent entry opportunity at the moment. Prices have been extended to the downside lately. For a nice entry it is better to wait for a consolidation. For an up to date full technical analysis you can check the technical report of XERS Concluding Our High Growth Momentum + Trend Template screen will find you more ideas which meet the Minervini criteria. Keep in mind Important Note: The content of this article is not intended as trading advice. It is essential to perform your own analysis and exercise caution when making trading decisions. The article presents observations created by automated analysis but does not guarantee any trading or investment outcomes. Always trade responsibly and make independent judgments.
Would Mark Minervini consider XERIS BIOPHARMA HOLDINGS INC (NASDAQ:XERS) a top stock pick?
You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research.
Start Your Free Trial Now!Not sure where to invest today?
Kalkine’s latest research highlights three companies identified through in-depth analysis and market insights.
Explore these research reports to learn about companies currently being tracked by our analysts and make more informed investment decisions.
View 3 Research ReportsThis information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
Please wait processing your request...